Diagnosing Insulin Resistance in Women with PCOS: A Stepwise Approach
Screen all women with PCOS for insulin resistance using an oral glucose tolerance test (OGTT), as this is the recommended office-based method that simultaneously detects both insulin resistance and glucose intolerance—the latter having greater prognostic and treatment implications 1.
When to Screen
Perform metabolic screening at the time of PCOS diagnosis, particularly focusing on:
- All obese women with PCOS (BMI ≥25 kg/m²) 2
- Women with central obesity (waist circumference ≥88 cm) 3
- Those with additional risk factors: family history of diabetes, anovulation, or advancing age 4
Diagnostic Algorithm
Step 1: Primary Screening with OGTT
- Perform a 2-hour 75g oral glucose tolerance test with fasting and 2-hour glucose and insulin measurements 1, 5
- This identifies:
- Type 2 diabetes (4% of PCOS patients)
- Impaired glucose tolerance/prediabetes (20% of PCOS patients)
- Insulin resistance patterns 5
Critical pitfall: Fasting plasma glucose alone misses 41% of prediabetes cases and 20% of diabetes cases in PCOS—do not rely on it as a standalone test 5.
Step 2: Assess Insulin Resistance in Those Without Glucose Intolerance
If OGTT shows normal glucose tolerance, quantify insulin resistance using:
- HOMA-IR (Homeostatic Model Assessment): fasting glucose (mg/dL) × fasting insulin (μU/mL) / 405
- OR fasting and 2-hour insulin levels from the OGTT 5, 6
These methods show substantial agreement (κ = 0.70-0.73) and are practical for office use 5. Approximately 56% of PCOS women without glucose intolerance will have insulin resistance by these measures 5.
Step 3: Clinical Assessment
Look for stigmata of insulin resistance syndrome:
- Acanthosis nigricans and skin tags 1
- Hypertension
- Dyslipidemia
- Central obesity (waist circumference ≥88 cm) 2
Important distinction: Women with prediabetes or diabetes are presumed to have insulin resistance and don't require additional insulin sensitivity testing 5.
Alternative Screening Considerations
HbA1c can be used as an alternative to OGTT for detecting glucose intolerance, though it shows only fair agreement with OGTT (κ = 0.29) 5. The 2013 Endocrine Society guidelines recommend OGTT as the preferred screening tool 1, 4.
Avoid relying on obesity alone as a proxy for insulin resistance—it demonstrates only fair to slight agreement with actual insulin resistance measures (κ = 0.18-0.33) 5.
Clinical Significance
Approximately 50-70% of women with PCOS have insulin resistance 2. Higher prepregnancy insulin resistance (highest HOMA-IR quartile) is associated with:
- Decreased ovulation rates (73.8% vs 93.5% in lowest quartile)
- Lower live birth rates (18.2% vs 35.5%)
- Dramatically increased gestational diabetes risk (45.7% vs 13.8%) 7
Progressive worsening occurs: Women with PCOS and obesity show pronounced upward IR trajectories over time, while those without obesity may show stable or improving patterns 3.
Treatment Threshold
Once insulin resistance or glucose intolerance is identified:
- Lifestyle modification (calorie-restricted diet and exercise) is first-line therapy for all overweight/obese women 1
- Metformin is recommended for women with type 2 diabetes or impaired glucose tolerance who fail lifestyle modification 1
- Metformin should NOT be used as first-line treatment for obesity, cutaneous manifestations, or pregnancy prevention 1
The euglycemic-hyperinsulinemic clamp is the gold standard for measuring insulin sensitivity but is impractical for clinical use due to cost and complexity 2, 6.